Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 211Neoplasm Metastasis 16Neoplasms 9Breast Neoplasms, Male 7Breast Diseases 7Ovarian Neoplasms 4Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Recurrence 2Prostatic Neoplasms 2Neoplasms by Site 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexuality 1Sexual Dysfunctions, Psychological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Breast Cancer ER+ve 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1enzalutamide 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lethal Congenital Contracture Syndrome 2 × exemestane × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡